Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02911571 · ClinicalTrials.gov registry record · NA
PRospective Multiple Myeloma Impact Study
A NA study of Multiple Myeloma, sponsored by SkylineDx.
- Active
- Registry status
- NA
- Development phase
- 250
- Enrollment target
- 9
- Study locations
NCT02911571: Active NA study of Multiple Myeloma, sponsored by SkylineDx.
NCT02911571 is a NA study of Multiple Myeloma that is active but no longer recruiting, run by SkylineDx. The registered enrollment target is 250 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (54% lower). The trial reports 9 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02911571, a NA study of Multiple Myeloma, is active but no longer recruiting, sponsored by SkylineDx.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 250 participants
- Enrollment target
- 9
- Study locations
Study Summary
This will be a prospective, case-only, study to measure the impact of MMprofiler on treatment intention decisions in Multiple Myeloma patients.
Primary Outcome
Change in treatment intention will be assessed with a physician questionnaire pre- and post MMprofiler assessment
Conditions Studied
Interventions
- DEVICE MMprofiler SKY92 gene signature
Study Locations (9)
New York
- New York Presbyterian Brooklyn Methodist Hospital - Brooklyn
- Columbia University Medical Center - New York
- Weill Cornell Medicine - New York
North Carolina
- Levine Cancer Institute - Charlotte
- Wake Forest Baptist Medical Center, - Winston-Salem
District of Columbia
- Lombardi Comprehensive Cancer Center - Washington D.C.
Georgia
- Winship Cancer Institute, Emory University - Atlanta
New Jersey
- Hackensack University Medical Center - Hackensack
Wisconsin
- Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2018-02-27 |
| Est. Completion | 2026-09-01 |
| Phase | NA |
What the registry record for NCT02911571 still lists
NCT02911571 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (54% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which MMprofiler SKY92 gene signature is the first listed.
NCT02911571 lists 9 locations in 6 states (New York, North Carolina, District of Columbia).
Frequently Asked Questions
What is clinical trial NCT02911571 about?
NCT02911571 is a clinical study titled "PRospective Multiple Myeloma Impact Study". This will be a prospective, case-only, study to measure the impact of MMprofiler on treatment intention decisions in Multiple Myeloma patients.
What is the current status of trial NCT02911571?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 250 participants. The study started on 2018-02-27. Estimated completion is 2026-09-01.
What conditions does trial NCT02911571 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT02911571?
The interventions under investigation include: MMprofiler SKY92 gene signature (DEVICE).
Who is sponsoring clinical trial NCT02911571?
This trial is sponsored by SkylineDx, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02911571 being conducted?
This trial has 9 study locations across District of Columbia, Georgia, New Jersey, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02911571's enrollment target sits among peer trials
250 88th of 438 higher than 347 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
RECRUITING · NA
-
An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers
RECRUITING · NA
-
Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
RECRUITING · NA
-
Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)
RECRUITING · NA
-
Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Stem Cell Transplantation
RECRUITING · NA
-
Prehabilitation Feasibility Among Older Adults Undergoing Transplantation
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI